4-(4-Ethylphenylmethyl)-1-trimethylsilylpyrazole | 1057216-12-2

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 4-(4-Ethylphenylmethyl)-1-trimethylsilylpyrazole
• 英文别名: [4-[(4-ethylphenyl)methyl]pyrazol-1-yl]-trimethylsilane
• CAS: 1057216-12-2
• 化学式: C₁₅H₂₂N₂Si
• 分子量: 258.439
• InChiKey: OTFNZKIIHZJZIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.72
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (5R)-5-acetoxy-1,2,3,4-tetra-O-acetyl-β-D-xylopyranose 、 4-(4-Ethylphenylmethyl)-1-trimethylsilylpyrazole 在 三氟甲磺酸三甲基硅酯 作用下， 以 顺-1,2-二氯乙烯 为溶剂， 生成
  参考文献：
  名称：

  N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors

  摘要：

  Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.042
• 作为产物：
  描述：

  3,5-Diamino-4-(4-ethylphenylmethyl)pyrazole 在 次磷酸 、 sodium nitrite 作用下， 以 水 、 乙腈 为溶剂， 生成 4-(4-Ethylphenylmethyl)-1-trimethylsilylpyrazole
  参考文献：
  名称：

  N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors

  摘要：

  Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.08.042
• 作为试剂：
  描述：

  4-(4-Ethylphenylmethyl)pyrazole 、 N,O-Bis(trimethylsilyl)acetamide 、 、 、 、 β-D-葡萄糖五乙酸酯 、 三氟甲磺酸三甲基硅酯 在 氩 、 4-(4-Ethylphenylmethyl)-1-trimethylsilylpyrazole 、 碳酸氢钠 、 二氯甲烷 、 Sodium sulfate-III 、 silica gel 、 正己烷 、 乙酸乙酯 作用下， 以 乙腈 、 1,1-二氯乙烷 为溶剂， 反应 5.5h， 以to give 4-(4-ethylphenylmethyl)-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)pyrazole 39 (610 mg) as a colorless semisolid的产率得到4-(4-ethylphenylmethyl)-1-(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl) pyrazole
  参考文献：
  名称：

  GLUCOPYRANOSIDE COMPOUND

  摘要：

  该化合物的化学式为：其中环A和环B为：（1）环A为可选取代的不饱和单环杂环环，环B为可选取代的不饱和单环杂环环，可选取代的不饱和融合杂双环环或可选取代的苯环，（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环环或可选取代的不饱和融合杂双环环，或（3）环A为可选取代的不饱和融合杂双环环，环B独立地为可选取代的不饱和单环杂环环，可选取代的不饱和融合杂双环环或可选取代的苯环；X为碳原子或氮原子；Y为—（CH2）n—（n为1或2）；或其药学上可接受的盐或前药。

  公开号：

  US20110105424A1

文献信息

• Novel compounds
  申请人：Nomura Sumihiro

  公开号：US20050233988A1

  公开（公告）日：2005-10-20

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  一种化合物，其化学式为：其中环A和环B分别为：（1）环A为可选取代的不饱和单环杂环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环；或（3）环A为可选取代的不饱和融合杂双环，环B独立地为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X为碳原子或氮原子；Y为—（CH2）n—（n为1或2）；其药学上可接受的盐或其前药。
• Glucopyranoside compound
  申请人：Nomura Sumihiro

  公开号：US08785403B2

  公开（公告）日：2014-07-22

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  该化合物的化学式为：其中环A和环B分别为：(1) 环A为可选取代的不饱和单环杂环环，环B为可选取代的不饱和单环杂环环、可选取代的不饱和融合杂双环环或可选取代的苯环，(2) 环A为可选取代的苯环，环B为可选取代的不饱和单环杂环环或可选取代的不饱和融合杂双环环，或(3) 环A为可选取代的不饱和融合杂双环环，环B独立地为可选取代的不饱和单环杂环环、可选取代的不饱和融合杂双环环或可选取代的苯环；X为碳原子或氮原子；Y为—(CH2)n—(n为1或2)；或其药学上可接受的盐或前药。
• N-glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors
  作者：Yasuo Yamamoto、Eiji Kawanishi、Yuichi Koga、Shigeki Sakamaki、Toshiaki Sakamoto、Kiichiro Ueta、Yasuaki Matsushita、Chiaki Kuriyama、Minoru Tsuda-Tsukimoto、Sumihiro Nomura

  DOI：10.1016/j.bmcl.2013.08.042

  日期：2013.10

  Inhibition of renal sodium-dependent glucose cotransporter 2 (SGLT2) increases urinary glucose excretion (UGE), and thus reduces blood glucose levels in hyperglycemia. A series of N-glucosides was synthesized for biological evaluation as human SGLT2 (hSGLT2) inhibitors. Among these compounds, N-glucoside 9d possessing an indole core structure showed good in vitro activity (IC50 = 7.1 nM against hSGLT2). Furthermore, 9d exhibited favorable in vivo potency with regard to UGE in rats based on good pharmacokinetic profiles. (C) 2013 Elsevier Ltd. All rights reserved.
• GLUCOPYRANOSIDE COMPOUND
  申请人：NOMURA Sumihiro

  公开号：US20120258913A1

  公开（公告）日：2012-10-11

  A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH 2 ) n — (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  一种化合物的公式：其中环A和环B是：(1) 环A是一个可选取代的不饱和单环杂环，环B是一个可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，(2) 环A是一个可选取代的苯环，环B是一个可选取代的不饱和单环杂环或可选取代的不饱和融合杂双环，或(3) 环A是一个可选取代的不饱和融合杂双环，环B是独立的可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环；X是一个碳原子或氮原子；Y是—(CH2)n—(n为1或2)；或其药学上可接受的盐或前药。